Johnson & Johnson preps for esketamine filing in resistant depression, despite a missed trial - FierceBiotech

FierceBiotechJohnson & Johnson preps for esketamine filing in resistant depression, despite a missed trialFierceBiotechA new type of drug for depression has been a long time coming, and Johnson & Johnson is looking increasingly likely to end the drought with esketamine—even though one of its late-stage trials missed the mark. Two studies reported at the American ...J&J's ketamine-based antidepressant sees mixed results in Phase 3BioPharma DiveEsketamine Nasal Spray Demonstrates Rapid Improvements in Treatment-Resistant DepressionMD MagazineEsketamine Nasal Spray Posts Positive Results in Two Phase 3 TrialsPsych Congress NetworkStreetInsider.com -Benzingaall 14 news articles »